Chronic renal allograft dysfunction

Journal of the American Society of Nephrology

Volumn 16, Issue 10, 2005, Pages 3015-3026

  Chapman, Jeremy R ^a,b   O'Connell, Philip J ^a   Nankivell, Brian J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; EDETATE CHROMIUM CR 51; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTETATE TECHNETIUM TC 99M; RAPAMYCIN;

ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; DISEASE EXACERBATION; DISEASE SEVERITY; FIBROSING ALVEOLITIS; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GRAFT REJECTION; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; HYALINE DEGENERATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; KIDNEY TUBULE FUNCTION; NEPHROTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; REPERFUSION INJURY; RISK FACTOR; TREATMENT FAILURE; CHRONIC DISEASE; FIBROSIS; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

CHRONIC DISEASE; FIBROSIS; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; TREATMENT FAILURE;

EID: 31644434259     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005050463     Document Type: Article

References (109)

1. ANZDATA Registry Report 2004. Edited by McDonald S, Excell L. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia
2. Meier-Kriesche HU, Schold JD, Kaplan B: Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 4: 1289-1295, 2004
3. US Renal Data System. USRDS 2004 Annual Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004
4. Jaffe M. Uber den niederschlag welchen pikrinsaure in normalem harn erzeugt and uber eine neu reacktion des kretainins. Z Physiol Chem 10: 391, 1886
5. Sigman EM, Elwood CM, Knox F: Measurement of GFR in man with sodium iothalamate 131-I (Conray). J Nucl Med 7: 60-68, 1965
6. Garnett EJ, Parsons V, Veall N: Measurement of GFR in man using 51Cr EDTA complex. Lancet 1: 818-821, 1967
7. Carlsen JE, Moller ML, Lund JO, Trap-Jensen J: Comparison of four commercial 99mTc(Sn) DTPA preparations used for the measurement of glomerular filtration rate. J Nucl Med 21: 126-129, 1980
8. Nankivell BJ, Grunewald S, Chapman JR: Assessment of renal function after kidney transplantation. Transplantation Reviews 10: 138-149, 1996
9. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976
10. Bjornsson TD: Use of serum creatinine concentrations to determine renal function. Clin Pharmacokinet 4: 200-222, 1979
11. Davis GA, Chandler MH: Comparison of creatinine clearance estimation methods in patients with trauma. Am J Health Syst Pharm 53: 1028-1032, 1996
12. Edwards KDG, Whyte HM: Plasma creatinine level and creatinine clearance as tests of renal function. Aust Ann Med 8: 218-224, 1959
13. Gates GF: Creatinine clearance estimates form serum are- atinine values: An analysis of three mathematical models of glomerular function. Am J Kidney Dis 5:199-205, 1985
14. Hull JH, Hak LJ, Koch GG, Wargin WA, Chi SL, Mattocks AM: Influence of range of renal function and liver disease on predictability of creatinine clearance. Clin Pharmacol Ther 29: 516-521, 1981
15. Jellife RW: Estimation of creatinine clearance when urine cannot be collected. Lancet 1: 975-976, 1971
16. Jellife RW: Creatinine clearance: Bedside estimate. Ann Intern Med 79: 604-605, 1973
17. Mawer GE, Lucas SB, Knowles BR, Stirland RM: Computer assisted prescribing of kanamycin for patients with renal insufficiency. Lancet 1: 12-15, 1972
18. Levey AS, Bosch JP, Lewis JB, Greene T, Roth DA: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999
19. Walser M, Drew HH, Guldan JL: Prediction of glomerular filtration rate from serum creatinine concentration in advanced chronic renal failure. Kidney Int 44: 1145-1148, 1993
20. Nankivell BJ, Grunewald S, Allen RDM, Chapman JR: Prediction of glomerular filtration rate in kidney transplantation. Transplantation 59: 1683-1689, 1995
21. Gaspari F, Ferrari S, Stucchi N, Centemeri E, Carrara F, Pellegrino M, Gherardi G, Gotti E, Segoloni G, Salvadori M, Rigotti P, Valente U, Donati D, Sandrini S, Sparacino V, Remuzzi G, Perico N: Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 4: 1826-1835, 2004
22. Raju DL, Grover VK, Shoker A: Limitations of glomerular filtration rate equations in the renal transplant patient. Clin Transplant 9: 259-268, 2005
23. Rodrigo E, Fernandez-Fresnedo G, Ruiz JC, Pinera C, Heras M, de Francisco AL, Sanz de Castro S, Cotorruelo JG, Zubimendi JA, Arias M: Assessment of glomerular filtration rate in transplant recipients with severe renal insufficiency by Nankivell, Modification of Diet in Renal Disease (MDRD), and Cockroft-Gault equations. Transplant Proc 35: 1671-1672, 2003
24. Lin J, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 14: 2573-2580, 2003
25. Schaub S, Rush D, Wilkins J, Gibson IW, Weiler T, Sangster K, Nicolle L, Karpinski M, Jeffery J, Nickerson P: Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 15: 219-227, 2004
26. Li B, Hartono C, Ding R, Sharma VK, Ramaswamy R, Qian B, Serur D, Mouradian J, Schwartz JE, Suthanthiran M: Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perform and granzyme B in urine. N Engl J Med 344: 947-954, 2001
27. Radermacher J, Mengel M, Ellis S, Stuht S, Hiss M, Schwarz A, Eisenberger U, Burg M, Luft FC, Gwinner W, Haller H: The renal arterial resistance index and renal allograft survival. N Engl J Med 349: 115-124, 2003
28. Nankivell BJ, Chapman JR, Gruenewald SM: Detection of chronic allograft nephropathy by quantitative Doppler imaging. Transplantation 74: 90-96, 2002
29. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y: The Banff 97 working classification of renal allograft pathology. Kidney Int 55: 713-723, 1999
30. O'Reilly P, Aurell M, Britton K, Kletter K, Rosenthal L, Testa T: Consensus on diuresis renography for investigating the dilated upper urinary tract. J Nucl Med 37: 1872-1876, 1996
31. Dubovsky EV, Russell CD, Erbas B: Radionuclide evaluation of renal transplants. Semin Nucl Med 25: 49, 1995
32. Kellar H, Nolodge G, Wilms G, Kirste G: Incidence, diagnosis and treatment of ureteric stenosis in 1928 renal transplant patients. Transplant Int 7: 253, 1994
33. Nankivell BJ, Cohn DA, Spicer ST, Evans SG, Chapman JR, Grunewald SM: Diagnosis of kidney transplant obstruction using Mag3 diuretic renography. Clin Transplantation 15: 11-18, 2001
34. Hunsicker LG, Bennett LE: Acute rejection reduces creatinine clearance at 6 months following renal transplantation but does not affect subsequent slope of Ccr. Transplantation 67: S83, 1999
35. Gourishankar S, Hunsicker LG, Jhangri GS, Cockfield SM, Halloran PF: The stability of the glomerular filtration rate after renal transplantation is improving. J Am Soc Nephrol 14: 2387-2394, 2003
36. Bertolatus JA, Friedlander MA, Scheldt C, Hunsciker LG: Urinary albumin excretion after donor nephrectomy. Am J Kidney Dis 5:165-169, 1985
37. Hume DM, Sterling WA, Weymouth RJ, Siebel HR, Madge GE, Lee HM: Glomerulonephritis in human renal homotransplants. Transplant Proc 2: 361, 1970
38. Honkanen E, Tornroth T, Pettersson E, Kuhlback B: Glomerulonephritis in renal allografts: Results of 18 years of transplantations. Clinical Nephrology 21: 210-219, 1984
39. Levy M, Charpentier B: De-novo membranous glomerulonephritis in renal allografts: Report of 19 cases in 1550 transplant recipients. Transplant Proc 15: 1099-1102, 1983
40. Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban S: Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 347: 103-109, 2002
41. Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, PeIz CJ, Roza AM, Vincenti F, George V: Recurrent and de novo glomerular disease after renal transplantation: A report from Renal Allograft Disease Registry (RADR). Transplantation 68:635-641, 1999
42. Purighalla R, Shapiro R, McCauley J, Randhawa P: BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis 26: 671-673, 1995
43. Lipshutz GS, Flechner SM, Govani MV, Vincenti F: BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 4: 2132-2134, 2004
44. Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J: Prospective study of polyomavirus type BK replication and nephropathy in renal transplant recipients. N Engl J Med 347: 488-496, 2002
45. Binet IF, Nickeleit V, Hirsch HH, Prince O, Dalquen P, Gudat F, Mihatsch MJ, Thiel G: Polyoma virus disease under new immunosuppressive drugs: A cause of renal graft dysfunction and graft loss. Transplantation 67: 918-922, 1999
46. Colvin RB, Mauiyyedi S: Differential diagnosis between infection and rejection in renal allografts. Transplant Proc 33: 1778-1779, 2001
47. Nickeleit V, Klimkait T, Binet IF, Dalquen P, Del Zenero V, Thiel G, Mihatsch MJ, Hirsch HH: Testing for polyoma virus type BK DNA in plasma to identify renal recipients with viral nephropathy. N Engl J Med 1309-1315,2000
48. Howell DN, Smith SR, Butterly DW, Klassen PS, Krigman HR, Burchette JL Jr, Miller SE: Diagnosis and management of BK polymavirus interstitial nephritis in renal transplant recipients. Transplantation 68: 1279-1288, 1999
49. Mannon RB: Polyomavirus nephropathy: What have we learned? Transplantation 77: 1313-1318, 2004
50. Wali RK, Drachenberg C, Hirsch HH Papadimitriou J, Nahar A, Mohanlal V, Brisco MA Bartlett ST, Weir MR, Ramos E: BK virus-associated nephropathy in renal allograft recipients: Rescue therapy by sirolimus-based immunosuppression. Transplantation 78: 1069-1073, 2004
51. Williams JW, Javaid B, Kadambi PV, Gillen D, Harland R, Thistlewaite JR, Garfinkel M, Foster P, Atwood W, Millis JM, Meehan SM, Josephson MA: Leflunomide or polyomavirus type BK nephropathy. N Engl J Med 352: 1157-1158, 2005
52. Lim WH, Mathew TH, Cooper JE, Bowden S, Russ GR: Use of cidofovir in polyomavirus BK viral nephropathy in two renal allograft recipients. Nephrology (Carlton) 8: 318-323, 2003
53. Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, Liang R, Lie AK, Kwong YL: Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 40: 528-537, 2005
54. Nankivell BJ, Fenton-Lee CA, Kuypers DR, Cheung E Allen RD, O'Connell PJ, Chapman JR: Effect of histological damage on long-term kidney transplant outcome. Transplantation 71: 515-523, 2001
55. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11: 1910-1917, 2000
56. Mullee M, Mason JC, Peveler RC: Frequency and impact of non-adherence to immunosuppressants following renal transplantation: A systematic review. Transplantation 77: 769-776, 2004.
57. Chapman JR: Compliance: The patient, the doctor and the medication? Transplantation 77: 782-786, 2004
58. Solez K: International standardization of criteria for histologic diagnosis of chronic rejection in renal allografts. Clin Transplant 8: 345-350, 1994
59. Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croker BP, Droz D, Dunnill MS, Halloran PF, et al: International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 44: 411-422, 1993
60. Dean DE, Kamath S, Peddi VR, Schroeder TJ, First MR, Cavallo T: A blinded retrospective analysis of renal allograft pathology using the Banff schema: Implications for clinical management. Transplantation 68: 642-645, 1999
61. Isonemi H, Takinen E, Hayry P: Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 58: 1195, 1994
62. Colvin RB: Chronic allograft nephropathy. N Engl J Med 349: 2288-2290, 2003
63. Furness PN, Taub N: International variation in the interpretation of renal transplant biopsies: Report of the CERT-PAP Project. Kidney Int 60: 1998-2012, 2001
64. Gough J, Rush D, Jeffery J, Nickerson P, McKenna R, Solez K, Trpkov K: Reproducibility of the Banff schema in reporting protocol biopsies of stable renal allografts. Nephrol Dial Transplant 17: 1081-1084, 2002
65. Furness PN, Philpott CM, Chorbadjian MT, Nicholson ML, Bosmans JL, Corthouts BL, Bogers JJ, Schwarz A, Gwinner W, Haller H, Mengel M, Seron D, Moreso F, Canas C: Protocol biopsy of the stable renal transplant: A multicenter study of methods and complication rates. Transplantation 76: 969-973, 2003
66. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326-2333, 2003
67. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 78: 242-249, 2004
68. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD: Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 78: 434-441, 2004
69. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 78: 461-468, 2004
70. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 78: 557-565, 2004
71. Fernando GC, Griffin MD, Grande JP, Lager DJ, Gloor JM, Velosa JA, Larson TS, Stegall MD: Development of chronic allograft nephropathy (CAN) in low risk kidney transplant recipients. Am J Transplant 4:278, 2004
72. Solez K, Vincenti F, Filo R: Histopathological findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 kidney transplant study group. Transplantation 66: 1736-1740, 1998
73. Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, Claesson K, Castagneto M, Campistol JM, Hutchison B, Burke JT, Yilmaz S, Hayry P, Neylan JF: Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4: 953-961, 2004
74. Merville P, Berge F, Deminiere C, Morel D, Chong G, Durand D, Rostaing L, Mourad G, Potaux L. Lower incidence of chorine allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant 4: 1769-1775, 2004
75. Schwarz A, Mengel M, Gwinner W, Radermacher J, Hiss, Kreipe H, Haller H: Risk factors for chronic allograft nephropathy after renal transplantation: A protocol biopsy study. Kidney Int 67: 341-348, 2005
76. Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H, Hammond JA, Whisenant T, Lanigan CM, Head SR, Salomon DR: De novo kidney transplantation without the use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 4: 1776-1785, 2004
77. Kuypers DR, Chapman JR, O'Connell PJ, Allen RD, Nankivell BJ: Predictors of renal transplant histology at three months. Transplantation 67: 1222-1230, 1999
78. Halloran PF, Wadgymer A, Ritchie S, Falk J, Solez K, Srinivasa NS: The significance of anti-class I antibody responses. I. Clinical and pathological features of anti-class I mediated rejection. Transplantation 49: 85-91, 1990
79. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K: Antibody-mediated rejection criteria: An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 3: 708-714, 2003
80. Lee PC, Terasaki PI, Takemoto SK, Lee PH, Hung CJ, Chen YL, Tsai A, Lei HY: All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 74: 1192-1194, 2002
81. Bohmig GA, Exner M, Habicht A, Schillinger M, Lang U, Kletzmayr J, Saemann MD, Horl WH, Watschinger B, Regele H: Capillary C4d deposition in kidney allografts: A specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 13: 1091-1099, 2002
82. Vongwiwatana A, Gourishankar S, Campbell PM, Solez K, Halloran PF: Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant 4: 124-129, 2004
83. Sijpkens YW, Joosten SA, Wong MC, Dekker FW, Benediktsson H, Bajema IM, Bruijn JA, Paul LC: Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 65: 2409-2418, 2004
84. Jin YP, Jindra PT, Gong KW, Lepin EJ, Reed EF: Anti-class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 79: S19-S21, 2005
85. Hamburger J Crosnier J, Dormont J: Observations in patients with a new tolerated homotransplant kidney: Possibility of a new secondary disease. Ann N Y Acad Sci 120: 558-577, 1964
86. Joosten SA, Sijpkens YWJ, van Ham V, Trouw LA, van der Vlag J, van den Heuval B, van Kooten C, Paul LC: Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 5: 383-393, 2005
87. Suri DL, Tomlanovich Sj, Olsen JL, Meyer TW: Transplant glomerulopathy as a cause of late graft loss. Am J Kidney Dis 35: 674-680, 2000
88. Rush D, Nickerson P, Gough J, McKenna R, Grimm P, Cheang M, Trpkov K, Solez K, Jeffery J: Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 9: 2129-2134, 1998
89. Moreso F, Alperovich G, Fulladosa X, Gil-Vernet S, Ibernon M, Carrera M, Castelao AM, Hueso M, Grinyo JM, Seron D: Histologic findings in protocol biopsies performed in stable renal allografts under different immunosuppressive schedules. Transplant Proc 35:1666-1668, 2003
90. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11: 1910-1917, 2000
91. Hilbrands LB, Hoitsma AJ, Koene KA: Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation. Transplantation 61: 1038-1046, 1996
92. Gallagher MP, Hall B, Craig J, Berry G, Tiller DJ, Eris J: A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 78: 1653-1660, 2004
93. Merville P, Berge F, Deminiere C, Morel D, Chong G, Durand D, Rostaing L, Mourad G, Potaux L: Lower incidence of chronic allograft nephropathy at 1 year post transplantation in patients treated with mycophenolate mofetil. Am J Transplant 4: 1769-1775, 2004
94. Dudley C, Pohanka E, Riad H, Dedochova J, Wijngaard, Sutter C, Tedesco-Silva H: Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" study. Transplantation 79: 466-475, 2005
95. Groth CG, Backman L, Morales JM: Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattstrom C, Charpentier B. Sirolimus (rapamycin) based therapy in human renal transplantation. Transplantation 67: 1036-1042, 1999
96. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthouz FC, Brattstrom C, Lebranchu Y, Vialtel P: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69: 1252-1260, 2000
97. Kahan BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicentre study. The Rappamune US Study Group. Lancet 356: 194, 2000
98. MacDonald AS: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71: 271-276, 2001
99. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T: Everolimus and reduced exposure cyclosporine in de-novo renal transplant recipients: A three year phase II, randomized, multicenter, open label study. Transplantation 9:1332-1340, 2004
100. Vitko S, Margreiter R, Weimar W, Dantal J, Viljoen HG, Yulan L, Jappe A, Cretin N: Everolimus (certican) 12 month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 78: 1532-1540, 2004
101. Napoli KL, Wang ME, Stepkowski SM, Kahan BD: Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions. Ther Drug Monit 20:123-133, 1998
102. Johnson RWG, Kries H, Oberbauer R, Brattstrom C, Claesson K, Eris J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72: 777-786, 2001
103. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, Burke JT, Brault Y, Gioud-Paquet M, Scarola JA, Neylan JF. Long term benefits with sirolimus based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15: 809-817, 2004
104. Stallone G, Di Paolo S, Schena A, Infante B, Grandiliano G, Battaglia M, Gesualdo L, Scehna FP: Early withdrawal of cyclosporine improves 1 year kidney graft structure and function in sirolimus treated patients. Transplantation 75: 998-1003, 2003
105. Ruiz JC, Campistol JM, Grinyo JM, Mota A, Prats D, Gutierrez JA, Henriques AC, Pinto JR, Garcia J, Morales JM, Gomez JM, Arias M: Early cyclosporine A withdrawal in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 78: 1312-1318, 2004
106. Pascual J: Concentration controlled everolimus (certican): Combination with reduced dose calcineurin inhibitors. Transplantation 79: S76-S79, 2005
107. Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, Vanrenterghem Y: FTY720, a novel immunomodulator: Efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 77: 1826-1833, 2004
108. Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roohipour R, Carreno MR, Roth D, Ruiz P, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J: The use of campath-1H as induction therapy in renal transplantation: Preliminary results. Transplantation 78: 426-433, 2004
109. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC: Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74: 1070-1076, 2002